Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ATNM NASDAQ:CSCI NYSE:OSTX NASDAQ:SPRO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATNMActinium Pharmaceuticals$1.59+6.7%$1.58$1.03▼$8.64$49.60M-0.32521,438 shs165,924 shsCSCICOSCIENS Biopharma$3.77+5.1%$3.53$1.96▼$6.77$11.89M0.7611,084 shs19,334 shsOSTXOS Therapies$1.68+6.3%$1.74$1.12▼$7.00$47.21MN/A489,654 shs294,519 shsSPROSpero Therapeutics$2.47-0.8%$2.19$0.51▼$3.22$138.10M1.331.23 million shs865,146 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATNMActinium Pharmaceuticals-3.50%+5.94%+1.68%+21.20%-79.53%CSCICOSCIENS Biopharma-5.08%-5.86%-3.75%+21.84%+343,599,900.00%OSTXOS Therapies+1.28%-2.47%-13.19%+0.64%+157,999,900.00%SPROSpero Therapeutics-5.68%-15.31%-12.01%+236.49%+72.32%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATNMActinium Pharmaceuticals2.8013 of 5 stars3.45.00.00.02.90.00.6CSCICOSCIENS BiopharmaN/AN/AN/AN/AN/AN/AN/AN/AOSTXOS Therapies2.2208 of 5 stars3.70.00.00.01.61.70.6SPROSpero Therapeutics3.9092 of 5 stars3.33.00.04.72.70.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATNMActinium Pharmaceuticals 2.75Moderate Buy$4.00151.57% UpsideCSCICOSCIENS Biopharma 0.00N/AN/AN/AOSTXOS Therapies 3.40Buy$18.00971.43% UpsideSPROSpero Therapeutics 2.50Moderate Buy$5.00102.43% UpsideCurrent Analyst Ratings BreakdownLatest CSCI, ATNM, SPRO, and OSTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/14/2025OSTXOS TherapiesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.006/30/2025OSTXOS TherapiesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.006/24/2025ATNMActinium PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.006/24/2025OSTXOS TherapiesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.006/9/2025OSTXOS TherapiesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.005/15/2025OSTXOS TherapiesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.005/12/2025ATNMActinium PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.004/28/2025ATNMActinium PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.004/22/2025OSTXOS TherapiesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.00(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATNMActinium PharmaceuticalsN/AN/AN/AN/A$1.31 per shareN/ACSCICOSCIENS Biopharma$9.59M1.24N/AN/A$3.49 per share1.08OSTXOS TherapiesN/AN/AN/AN/AN/AN/ASPROSpero Therapeutics$28.30M4.88N/AN/A$0.85 per share2.91Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATNMActinium Pharmaceuticals-$48.82M-$1.47N/AN/AN/AN/A-100.85%-47.89%N/ACSCICOSCIENS Biopharma-$15.31M-$5.80N/A∞N/A-194.50%-101.01%-43.90%8/12/2025 (Estimated)OSTXOS Therapies-$7.79M-$0.86N/AN/AN/AN/AN/A-569.57%N/ASPROSpero Therapeutics-$68.57M-$1.28N/AN/AN/A-156.48%-123.50%-58.96%8/4/2025 (Estimated)Latest CSCI, ATNM, SPRO, and OSTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/4/2025Q2 2025SPROSpero Therapeutics-$0.35N/AN/AN/AN/AN/A5/13/2025Q1 2025CSCICOSCIENS BiopharmaN/A-$1.16N/A-$1.16N/A$1.50 million5/13/2025Q1 2025SPROSpero Therapeutics-$0.55-$0.25+$0.30-$0.25$11.00 million$5.87 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATNMActinium PharmaceuticalsN/AN/AN/AN/AN/ACSCICOSCIENS BiopharmaN/AN/AN/AN/AN/AOSTXOS TherapiesN/AN/AN/AN/AN/ASPROSpero Therapeutics$0.062.43%N/AN/A N/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATNMActinium PharmaceuticalsN/A10.2510.25CSCICOSCIENS BiopharmaN/A2.882.54OSTXOS TherapiesN/A0.760.76SPROSpero TherapeuticsN/A2.562.56Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATNMActinium Pharmaceuticals27.50%CSCICOSCIENS Biopharma0.73%OSTXOS TherapiesN/ASPROSpero Therapeutics25.60%Insider OwnershipCompanyInsider OwnershipATNMActinium Pharmaceuticals6.00%CSCICOSCIENS Biopharma0.10%OSTXOS Therapies13.80%SPROSpero Therapeutics5.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATNMActinium Pharmaceuticals3031.20 million29.32 millionOptionableCSCICOSCIENS Biopharma203.15 million3.14 millionN/AOSTXOS TherapiesN/A28.10 millionN/AN/ASPROSpero Therapeutics15055.91 million52.84 millionOptionableCSCI, ATNM, SPRO, and OSTX HeadlinesRecent News About These CompaniesSpero Therapeutics (NASDAQ:SPRO) Stock Passes Above Fifty Day Moving Average - What's Next?July 1, 2025 | marketbeat.comWhile institutions own 20% of Spero Therapeutics, Inc. (NASDAQ:SPRO), retail investors are its largest shareholders with 54% ownershipJune 28, 2025 | finance.yahoo.comSpero Therapeutics, Inc. (SPRO) Cash Flow - Yahoo FinanceJune 26, 2025 | finance.yahoo.comSpero Therapeutics (NASDAQ:SPRO) Upgraded to "Hold" at Wall Street ZenJune 21, 2025 | marketbeat.comSpero Therapeutics (NASDAQ:SPRO) Shares Pass Above 200 Day Moving Average - What's Next?June 19, 2025 | marketbeat.comSpero Therapeutics -- Additional Upside Potential Following Positive Phase 3 ResultsJune 11, 2025 | seekingalpha.comWhy Spero Therapeutics, Inc. (SPRO) Surged Last WeekMay 31, 2025 | msn.comWhy Spero Therapeutics, Inc. (SPRO) Surged Last WeekMay 31, 2025 | insidermonkey.comGSK & Spero Therapeutics announce PIVOT-PO phase III study for tebipenem HBr stopped early for efficacy following review by IDMCMay 30, 2025 | pharmabiz.comPSpero Therapeutics rockets on positive Phase III study for tebipenem HBrMay 29, 2025 | thepharmaletter.comTSpero Therapeutics Jumps as Oral Carbapenem Hits Phase 3 MilestoneMay 29, 2025 | msn.comSPRO Stock Soars 245% on GSK-Partnered UTI Drug Meeting Study GoalMay 29, 2025 | zacks.comGSK, Spero report Phase 3 win for UTI antibiotic; Spero's stock soarsMay 28, 2025 | endpts.comEGSK's $66M bet on Spero's rejected UTI antibiotic pays off with a phase 3 winMay 28, 2025 | fiercebiotech.comFSpero Therapeutics Shares Soar as Trial with GSK Ends Early on EfficacyMay 28, 2025 | marketwatch.comSpero Therapeutics Stock Skyrockets on Strong Phase 3 Trial ResultsMay 28, 2025 | msn.comSpero Therapeutics and GSK Announce PIVOT-PO Phase 3 Study for Tebipenem HBr Stopped Early for Efficacy Following Review by Independent Data Monitoring CommitteeMay 28, 2025 | globenewswire.comSpero Therapeutics, Inc. (SPRO) Reports Q1 Loss, Misses Revenue EstimatesMay 13, 2025 | zacks.comSpero Therapeutics Announces First Quarter 2025 Operating Results and Provides a Business UpdateMay 13, 2025 | globenewswire.comSpero Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on Tuesday, May 13, 2025May 5, 2025 | globenewswire.comSpero Therapeutics, Inc.: Spero Therapeutics Appoints Esther Rajavelu as President and Chief Executive OfficerApril 29, 2025 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir Soon3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military SpendIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeSmart Investors Are Watching These 3 Undervalued StocksBy Gabriel Osorio-Mazilli | July 12, 2025View Smart Investors Are Watching These 3 Undervalued StocksRussell Rebalance: 3 Stocks Ready to Move HigherBy Chris Markoch | June 20, 2025View Russell Rebalance: 3 Stocks Ready to Move HigherCSCI, ATNM, SPRO, and OSTX Company DescriptionsActinium Pharmaceuticals NYSE:ATNM$1.59 +0.10 (+6.71%) Closing price 04:00 PM EasternExtended Trading$1.59 0.00 (0.00%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.COSCIENS Biopharma NASDAQ:CSCI$3.77 +0.18 (+5.13%) Closing price 03:54 PM EasternExtended Trading$4.00 +0.23 (+6.12%) As of 07:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.COSCIENS Biopharma Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. In addition, it has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults; as well as The University of Sheffield, the United Kingdom for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism. The company was formerly known as Aeterna Zentaris Inc. and changed its name to COSCIENS Biopharma Inc. in August 2024. COSCIENS Biopharma Inc. was incorporated in 1990 and is headquartered in Toronto, Canada.OS Therapies NYSE:OSTX$1.68 +0.10 (+6.33%) Closing price 04:00 PM EasternExtended Trading$1.65 -0.03 (-1.67%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.Spero Therapeutics NASDAQ:SPRO$2.47 -0.02 (-0.80%) Closing price 04:00 PM EasternExtended Trading$2.52 +0.04 (+1.82%) As of 07:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AMD Just Triggered a Signal Traders Can’t Ignore JNJ’s Stock Price Is Back in Rally Mode—The Time to Buy Is Now This ASML Dip Could Be Gone Before You Know It—Don’t Miss Out Rocket Lab Gets New Street-High Price Target from Citi Super Micro Stock May Benefit as Cooling Demand Takes Off Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters 3 Analysts Set $600 Target Ahead of Microsoft Earnings Salesforce Stock Set for 30% Upside to Reach New Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
